Risankizumab for treating moderately to severely active ulcerative colitis

Final draft guidance

Final draft guidance (PDF 136 KB)

Equality impact assessment (PDF 127 KB)

Committee papers (PDF 4.63 MB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 188 KB)

Final stakeholder list (PDF 166 KB)

Final scope (PDF 197 KB)

Equality impact assessment (Scoping) (PDF 127 KB)

Draft matrix post referral (PDF 160 KB)

Draft scope post referral (PDF 210 KB)